Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias

Fabio Stagno Department of Biomedical Sciences, Section of Hematology, University of Catania, Italy; *These authors contributed equally to this workCorrespondence[email protected]

Paolo Vigneri Section of General Pathology, University of Catania, Italy; Medical Oncology Unit, Vittorio Emanuele University Hospital, Catania, Italy; *These authors contributed equally to this work

Vittorio Del Fabro Department of Biomedical Sciences, Section of Hematology, University of Catania, Italy

Stefania Stella Section of General Pathology, University of Catania, Italy

Nunzio Restuccia Medical Oncology Unit, Vittorio Emanuele University Hospital, Catania, Italy

Cesarina Giallongo Department of Biomedical Sciences, Section of Hematology, University of Catania, Italy

Michele Massimino Section of General Pathology, University of Catania, Italy

Salvatore Berretta Department of Biomedical Sciences, Section of Hematology, University of Catania, Italy

Maria Stella Pennisi Section of General Pathology, University of Catania, Italy

Daniele Tibullo Department of Biomedical Sciences, Section of Hematology, University of Catania, Italy

Elena Tirrò Section of General Pathology, University of Catania, Italy

Calogero Buscarino Medical Oncology Unit, Vittorio Emanuele University Hospital, Catania, Italy

Angelo Messina Section of General Pathology, University of Catania, Italy

Francesco Di Raimondo Department of Biomedical Sciences, Section of Hematology, University of Catania, Italy

show all

"Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias." Acta Oncologica, 49(1), pp. 111–112

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias

Information for

Open access

Opportunities

Help and information

Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature